These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 17075587)

  • 21. The effect of testosterone replacement therapy on prostate-specific antigen (PSA) levels in men being treated for hypogonadism: a systematic review and meta-analysis.
    Kang DY; Li HJ
    Medicine (Baltimore); 2015 Jan; 94(3):e410. PubMed ID: 25621688
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
    Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
    Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of testosterone replacement therapy on serum PSA in patients with Klinefelter syndrome.
    Shibasaki T; Sasagawa I; Suzuki Y; Yazawa H; Ichiyanagi O; Matsuki S; Miura M; Nakada T
    Arch Androl; 2001; 47(3):173-6. PubMed ID: 11695839
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Postoperative prostate-specific antigen velocity independently predicts for failure of salvage radiotherapy after prostatectomy.
    King CR; Presti JC; Brooks JD; Gill H; Spiotto MT
    Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1472-7. PubMed ID: 17935902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
    Soga N; Onishi T; Arima K; Sugimura Y
    Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Failure to achieve a PSA level Mitchell DM; McAleese J; Park RM; Stewart DP; Stranex S; Eakin RL; Houston RF; O'Sullivan JM
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1467-71. PubMed ID: 17689886
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Testosterone replacement therapy for late onset hypogonadism: what is the risk of inducing prostate cancer?
    Gould DC; Kirby RS
    Prostate Cancer Prostatic Dis; 2006; 9(1):14-8. PubMed ID: 16264770
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
    Soga N; Arima K; Sugimura Y
    Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Repeating an abnormal prostate-specific antigen (PSA) level: how relevant is a decrease in PSA?
    Connolly D; Black A; Murray LJ; Nambirajan T; Keane PF; Gavin A
    Prostate Cancer Prostatic Dis; 2009; 12(1):47-51. PubMed ID: 18762815
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of body mass index and total testosterone level on biochemical recurrence following radical prostatectomy.
    Hisasue S; Yanase M; Shindo T; Iwaki H; Fukuta F; Nishida S; Muranaka T; Miyamoto S; Tsukamoto T; Takatsuka K
    Jpn J Clin Oncol; 2008 Feb; 38(2):129-33. PubMed ID: 18281308
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Time-course of plasma testosterone in patients with prostate cancer treated by endocrine therapy].
    Peyromaure M; Rebillard X; Ruffion A; Salomon L; Villers A; Soulie M;
    Prog Urol; 2008 Jan; 18(1):2-8. PubMed ID: 18342148
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate.
    Curran MJ; Bihrle W
    Urology; 1999 Feb; 53(2):423-4. PubMed ID: 9933071
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America.
    Gittelman M; Pommerville PJ; Persson BE; Jensen JK; Olesen TK;
    J Urol; 2008 Nov; 180(5):1986-92. PubMed ID: 18801505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical practice experience with testosterone treatment in men with testosterone deficiency syndrome.
    McLaren D; Siemens DR; Izard J; Black A; Morales A
    BJU Int; 2008 Nov; 102(9):1142-6. PubMed ID: 18540933
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate-specific antigen level at initiation of hormonal therapy after prostate-specific antigen failure following prostatectomy or radiotherapy and therapeutic response.
    Alexander BM; Chen MH; Carroll P; D'Amico AV
    Urology; 2007 Aug; 70(2):320-3. PubMed ID: 17826497
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Prostatic specific antigen: role and significance in urologic practice].
    Manolović D; Pejcić T; Milović N
    Srp Arh Celok Lek; 1994; 122(5-6):171-3. PubMed ID: 17977420
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Update of treatment for prostate cancer].
    Ito K
    Gan To Kagaku Ryoho; 2011 Jan; 38(1):48-53. PubMed ID: 21434292
    [No Abstract]   [Full Text] [Related]  

  • 38. Development of a nomogram for predicting high-grade prostate cancer on biopsy: the significance of serum testosterone levels.
    Ide H; Yasuda M; Nishio K; Saito K; Isotani S; Kamiyama Y; Muto S; Horie S
    Anticancer Res; 2008; 28(4C):2487-92. PubMed ID: 18751439
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
    Lilja H; Ulmert D; Vickers AJ
    Nat Rev Cancer; 2008 Apr; 8(4):268-78. PubMed ID: 18337732
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Prostate specific antigen: utilization modalities and interpretation].
    Hannoun-Levi JM; Ginot A; Thariat J
    Cancer Radiother; 2008 Dec; 12(8):848-55. PubMed ID: 18539498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.